This study is in progress, not accepting new patients
A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
Summary
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by J. Randolph Hecht, MD

Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- J. Randolph Hecht, MD
Dr. Joel R. Hecht holds the Carol and Saul Rosenzweig Endowed Chair for Cancer Therapies Development.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AstraZeneca
- Links
- Sign up for this study
- ID
- NCT06218914
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 24 study participants
- Last Updated